Comparison of Presenting Features and Three-year Disease Course in Turkish Patients with Behcet Uveitis Who Presented in the Early 1990s and the Early 2000s

Basit Öğe Kaydı
dc.contributor.authorCingu, Abdullah Kursat
dc.contributor.authorOnal, Sumru
dc.contributor.authorUrgancioglu, Meri
dc.contributor.authorTugal-Tutkun, Ilknur
dc.date.accessioned2024-04-24T17:20:29Z
dc.date.available2024-04-24T17:20:29Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: To compare Behcet uveitis patients who presented in the 1990s and 2000s. Methods: Records of 170 patients seen in 1990-1994 and 258 patients seen in 2000-2004 were reviewed. Presenting features were analyzed in the whole cohort. Uveitis attacks, vision, complications, and immunomodulatory treatment (IMT) were compared in patients with 3-year follow-up. Results: Posterior segment involvement was less common, visual acuity was better, and more patients received IMT before referral in the 2000s. Follow-up revealed no significant difference in number of uveitis attacks in the first 3 years. Less eyes lost useful vision, no patient became legally blind, and fewer severe ocular complications occurred in the 2000s. IMT was started within 3 months in more patients and interferon alfa-2a was used only in the latter study period. Conclusions: The findings suggest a milder disease at referral, lower rate of severe complications, and a better 3-year visual outcome in patients who presented in the early 2000s.en_US
dc.description.sponsorshipIRIS (Institut de Recherches Internationales Servier); Novartis Pharma AG; XOMA (US) LLC; Kowa Company; Novartis Turkey; Abbott Turkeyen_US
dc.description.sponsorshipIlknur Tugal-Tutkun has received financial support outside the submitted work, including honoraria from IRIS (Institut de Recherches Internationales Servier), Novartis Pharma AG and XOMA (US) LLC and Kowa Company, a research grant from Novartis Pharma AG and travel grants from Novartis Turkey and Abbott Turkey. No government and nongovernment funding support has been obtained. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.en_US
dc.identifier.doi10.3109/09273948.2012.713159
dc.identifier.endpage428en_US
dc.identifier.issn0927-3948
dc.identifier.issue6en_US
dc.identifier.pmid23163330
dc.identifier.scopus2-s2.0-84870878957
dc.identifier.scopusqualityQ1
dc.identifier.startpage423en_US
dc.identifier.urihttps://doi.org/10.3109/09273948.2012.713159
dc.identifier.urihttps://hdl.handle.net/11468/19083
dc.identifier.volume20en_US
dc.identifier.wosWOS:000312010300005
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherInforma Healthcareen_US
dc.relation.ispartofOcular Immunology and Inflammation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBehcet Uveitisen_US
dc.subjectImmunomodulatory Treatmenten_US
dc.subjectInterferon Alfa-2aen_US
dc.subjectPrognosisen_US
dc.subjectVisual Outcomeen_US
dc.titleComparison of Presenting Features and Three-year Disease Course in Turkish Patients with Behcet Uveitis Who Presented in the Early 1990s and the Early 2000sen_US
dc.titleComparison of Presenting Features and Three-year Disease Course in Turkish Patients with Behcet Uveitis Who Presented in the Early 1990s and the Early 2000s
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu